Table 1 Pretherapy Characteristics
Patient Characteristics | ARV-Naive (n = 49) | ARV-Experienced (n = 92) |
|---|---|---|
Age, median (range), y | 40 (28–68) | 39 (18–74) |
Sex | ||
Male (%) | 37 (75.5) | 71 (77.1) |
Female (%) | 11 (24.5) | 20 (22.9) |
WHO stage before initiating current or past ART | ||
Stage I | 15 (30.6) | 36 (39.1) |
Stage II | 5 (10.2) | 10 (10.9) |
Stage III | 5 (10.2) | 9 (9.9) |
Stage IV | 24 (49) | 37 (40.1) |
Duration of HIV infection since diagnosis months, median (range), y | 18.5 (3–161) | 38 (2–185) |
Pretherapy body mass index, median (range) | 21.365 (14.36–33.2) | 23.04 (12.3–35.16) |
Current pretherapy CD4 count, median (range) | 104.5 (6–330) | 309 (10–1259) |
Reasons for substituting | ||
Patients decision (mutually inclusive) | 47 | |
Stavudine (d4T)-related toxicity | 5 | |
Zidovudine (ZDV)-related toxicity | 20 | |
Dual toxicity (d4T and ZDV) | 29 | |
Convenience | 34 | |
Other (mostly co-infection with hepatitis B virus) | 7 | |
Co-infection with HBV | ||
HBsAg-positive | 3 (6.1) | 4 (4.3) |
HBsAg-negative | 29 (59.2) | 19 (20.7) |
Unknown | 17 (34.7) | 69 (75) |
Pretherapy renal function | ||
Serum creatinine (mg/dL), median (range) | 1 (0.5–1.9) | 1 (0.4–1.8) |
Creatinine clearance (mg/min), median (range) | 71.9 (38.1–145.5) | 87.4 (32.5–151.6) |